Celldex Therapeutics 8/8/2024 Earnings Report $23.72 +0.96 (+4.20%) As of 02:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Celldex Therapeutics EPS ResultsActual EPS-$0.54Consensus EPS -$0.59Beat/MissBeat by +$0.05One Year Ago EPSN/ACelldex Therapeutics Revenue ResultsActual Revenue$2.50 millionExpected Revenue$1.13 millionBeat/MissBeat by +$1.37 millionYoY Revenue GrowthN/ACelldex Therapeutics Announcement DetailsQuarterDate8/8/2024TimeAfter Market ClosesConference Call ResourcesPress ReleaseCLDX Earnings HistoryPowered by Celldex Therapeutics Earnings HeadlinesBuy Rating for Celldex: Strategic Market Position and Growth Potential Amid Jasper’s Delayed CompetitionJanuary 9, 2025 | markets.businessinsider.comCelldex Therapeutics, Inc.: Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic DermatitisDecember 20, 2024 | finanznachrichten.deWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.January 17, 2025 | Behind the Markets (Ad)Celldex initates Phase 2 study of barzolvolimab in ADDecember 20, 2024 | markets.businessinsider.comWhat Analysts Are Saying About Celldex Therapeutics StockDecember 20, 2024 | benzinga.comCelldex Therapeutics Inc (CLDX) Launches Phase 2 Study of Barzolvolimab for Atopic DermatitisDecember 19, 2024 | gurufocus.comSee More Celldex Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email. Email Address About Celldex TherapeuticsCelldex Therapeutics (NASDAQ:CLDX), a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.View Celldex Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Ameriprise Financial (1/22/2025)Amphenol (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
